Immunohistochemistry (IHC) Market

Immunohistochemistry (IHC) Market by Product (Antibodies, Reagents, Equipment, Kits), Application (Diagnostics (Cancer, Infectious, Autoimmune Diseases), Research, Forensic), End user (Hospitals, Diangostic labs, Academia) - Global Forecast to 2026

Report Code: BT 4780 Nov, 2021, by marketsandmarkets.com

[352 Pages Report] The global immunohistochemistry market is projected to reach USD 3.3 billion by 2026 from USD 2.3 billion in 2021, at a CAGR of 7.7% during the forecast period of 2021 to 2026. Market growth is largely driven by the rising geriatric population and subsequent growth in prevalence of chronic and infectious diseases, technological advancements in IHC, and availability of reimbursements for IHC tests. However, the high degree of consolidation in the by the major market players is expected to restrain the growth of this market during the forecast period.

Immunohistochemistry (IHC) Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 impact on the Immunohistochemistry Market

Coronavirus disease 2019 (COVID‐19) is an acute respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic in just a few weeks. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020. There has been a tremendous amount of effort put into developing new treatments and vaccines to cure the infection. Within a few weeks of research, companies started coming up with drugs and treatments to treat the infection.

Global Immunohistochemsitry Market Dynamics

DRIVER: The rising geriatric population and subsequent growth in prevalence of chronic and infectious diseases

The increasing geriatric population in developed as well as developing regions will positively influence the growth of the IHC market. With the rapid growth in the geriatric population globally, the prevalence of age-associated diseases is expected to increase significantly. According to the OECD, the number of elderly people living in the US was ~54 million in 2019. Other developed economies around the world also have large and growing geriatric populations. With age, the risk of developing diseases increases proportionately. Thus, the growth in the geriatric population is expected to increase the prevalence of various diseases across the globe. This is considered a key factor driving the growth of the IHC market for diagnostic applications.

RESTRAINTS: High degree of consolidation

The global immunohistochemistry market is consolidated at the top, with the top three companies—F. Hoffmann-La Roche AG (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US)—commanding a share of ~70%-80% in 2020.

Patent expiry of antibodies is a major challenge in the immunohistochemistry market. Some of the primary antibodies manufactured and marketed by F. Hoffmann-La Roche AG (Switzerland) and Merck (Germany) are nearing patent expiration. As a result, the overall revenue and profitability of these market players are decreasing. Moreover, industry players are facing challenges such as rising price pressure from governments across the globe and reduced R&D output. To overcome these challenges, large market players are acquiring smaller and mid-sized market players that have innovative patented products. This provides a large financial and distribution platform for these products to increase their coverage into new markets globally.

OPPORTUNITY: Increasing demand for personalized medicine

Personalized medicine for non-small-cell lung cancer patients has proven to be extremely effective, and its use is expected to increase in the future. Immunohistochemistry techniques support this approach to treatment decision-making by performing the most complete and accurate histological subtyping of tumors possible (supported by predictive immunohistochemistry and the assessment of relevant biomarkers). Moreover, the increased availability of immunohistochemistry assays that detect mutant proteins (e.g., BRAF V600E and IDH1 R132H) provides a helpful replacement and/or adjunct for molecular testing. These techniques are highly reproducible, entail reasonable technical and interpretation complexity, and are available at relatively lesser costs, making them valuable novel tools in modern cancer care. The development of multiplex and mutation-specific immunohistochemistry assays represents important innovations, which provide improved utility in the context of personalized medicine and targeted therapy.

CHALLENGES: Dearth of skilled professionals

The demand for pathology services has increased significantly for clinical applications due to the increasing prevalence of cancer. Histopathology technologies account for the majority of the tests performed on cancer patients. However, there is a dearth of trained staff in these laboratories. A large number of histopathologists have reached retirement age, and a small number of histopathologists are being trained. On the other hand, laboratories are under pressure to process an increasing number of specimens with limited staff.

Diagnostic applications segment accounted for the largest share of the application segment

Based on application, the IHC market is segmented into diagnostic, research, and forensic applications. The Diagnostic application segment dominated this market in 2020 and is estimated to register the highest growth during the forecast period. The growth of this segment is majorly attributed to factors such as the advantages of IHC over traditionally used special enzyme staining techniques that identify only a limited number of proteins, enzymes, and tissue structures. Therefore, IHC has become a crucial technique and is widely used for medical research as well as clinical diagnostics.

The antibodies segment accounted for the largest share in 2020

Based on product, the IHC market is segmented into antibodies, reagents, equipment, and kits. In 2020, the antibodies segment accounted for the largest share of 45.5% of the IHC market. Antibodies and Kits segment are seen to be the leading segments with respect to growth rate during the forecast period as a result of rapid development in the field of immunohistochemistry which has subsequently boosted the research and development of various antibodies in the past decade. Furthermore, antibodies are important diagnostic and therapeutic agents in immunology. Rising demand for complete solutions from a single provider and the advantage of simplification of IHC process is fuelling the growth of Kits segment.

Hospitals & Diagnostic Laboratories segment accounted for the largest share of the end user segment

Based on end user, the IHC market is segmented into hospitals & diagnostic laboratories, academic & research institutes, and other end users. The hospitals & diagnostic laboratories segment accounted for the largest share (74.8%) of the IHC market in 2020. The increasing number of specialty diagnostic tests performed in hospital laboratories, the rising number of in-house diagnostic procedures in hospitals, and the increasing trend of establishing in-house diagnostic capabilities in hospitals to provide time-bound and affordable patient services are factors driving the growth of this market segment.

Immunohistochemistry (IHC) Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America was the largest regional market for immunohistochemistry market in 2020.

Based on the region, the immunohistochemistry market is broadly segmented into North America, Europe, Asia-Pacific and Rest of the World. APAC is expected to register the fastest growth rate during the forecast period owing to several factors, including increasing disposable income, rising healthcare spending, growing demand for quality medical care, and increasing investments by pharmaceutical and biopharmaceutical companies. The rising prevalence of chronic ailments, rapidly increasing geriatric population, growing academic and government investments in diagnostic research, and the presence of many market players are the other major factors driving the growth of the immunohistochemistry market in APAC.

Key Market Players

Key players operating in the global immunohistochemistry market include F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2019–2026

Base year considered

2020

Forecast period

2021–2026

Forecast units

Value (USD)

Segments covered

Product, Application, End- User and Region

Geographies covered

North America, Europe, Asia Pacific, and Rest of the World

Companies covered

F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Bio-Techne Corporation (US), Abcam plc (UK), Becton, Dickinson and Company (US), PerkinElmer, Inc. (US), Takara Bio, Inc. (Japan), Thermo Fisher Scientific, Inc. (US), PHC Holdings Corporation (Japan), Cell Signaling Technology, Inc. (US), Bio SB, Inc. (US), Miltenyi Biotec (Germany), CANDOR Bioscience GmbH (Germany), Sakura Finetek Japan Co., Ltd. (Japan), Eagle Biosciences, Inc. (US), Biocare Medical, LLC (US), Elabscience, Inc. (China), Biogenex Laboratories (US), Diagnostic Biosystems, Inc. (US), BioVision Inc. (US), Rockland Immunochemicals, Inc. (US), and Genemed Biotechnologies, Inc. (US).

This report categorizes the immunohistochemistry market into the following segments and subsegments:

Immunohistochemistry Market, by Product

  • Antibodies
    • Primary antibodies
    • Secondary antibodies
  • Reagents
    • Histological Stains
    • Blocking Sera and Reagents
    • Chromogenic Substrates
    • Fixation Reagents
    • Organic Solvents
    • Proteolytic Enzymes
    • Diluents
    • Other Reagents (antigen retrieval solutions, stabilizers, controls, and mounting solutions)
  • Equipment
    • Slide-staining Systems
    • Tissue Processing Systems
    • Slide Scanners
    • Other Equipment (automated cover slippers, visualization equipment, microtomes, paraffin dispensers, slide labelers, and tissue microarrays)
  • Kits
    • IHC Kits for Human tissue
    • IHC Kits for Animal tissue

Immunohistochemistry Market, by Application

  • Diagnostic applications
    • Cancer
    • Infectious diseases
    • Autoimmune diseases
    • Nephrological diseases
    • Neurological diseases
    • Other diseases (ophthalmic, cardiovascular, dermatological, and dental diseases)
  • Research applications
    • Drug development and Testing
    • Other research applications (stem ell research and developmental biology)
  • Forensic applications

Immunohistochemistry Market, by End-user

  • Hospitals & Diagnostic Laboratories
  • Academic & research Institutes
  • Other end users (CROs, pharma & biopharma companies, and forensic laboratories)

Immunohistochemistry Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • Japan
    • China
    • India
    • Rest of Asia Pacific (RoAPAC)
  • Rest of the World (RoW)
    • Latin America
    • Middle East and Africa

Recent Developments

  • In August 2021, Roche received FDA approval for VENTANA MMR RxDx companion diagnostic test based on immunohistochemistry for solid tumors that are deficient in the MMR pathway. The test identifies patients eligible for GSK’s anti-PD1 immunotherapy, JEMPERLI.
  • In August 2021, Agilent received a CE-IVD mark in Europe for its PD-L1 IHC 22C3 pharmDx assay for the identification of oesophageal cancer patients for treatment with KEYTRUDA.

Frequently Asked Questions (FAQs):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 44)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
                    TABLE 1 IMMUNOHISTOCHEMISTRY MARKET: INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 50)
    2.1 RESEARCH DATA
           FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 2 BREAKDOWN OF PRIMARIES: IHC MARKET
    2.2 MARKET ESTIMATION METHODOLOGY
           FIGURE 3 IHC MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS) 2020
           FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2020
           2.2.1 INSIGHTS FROM PRIMARY EXPERTS
                    FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
    2.3 MARKET GROWTH RATE PROJECTIONS
           FIGURE 6 IHC MARKET (SUPPLY-SIDE): CAGR PROJECTIONS
           FIGURE 7 IHC MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS
    2.4 DATA TRIANGULATION
           FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.5 RESEARCH ASSUMPTIONS
           2.5.1 COVID-19 SPECIFIC ASSUMPTIONS
    2.6 RISK ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 61)
    FIGURE 9 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
    FIGURE 10 IMMUNOHISTOCHEMISTRY MARKET SHARE, BY APPLICATION, 2020
    FIGURE 11 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2021−2026
    FIGURE 12 GEOGRAPHICAL SNAPSHOT OF IMMUNOHISTOCHEMISTRY MARKET

4 PREMIUM INSIGHTS (Page No. - 64)
    4.1 IMMUNOHISTOCHEMISTRY MARKET OVERVIEW
           FIGURE 13 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH
    4.2 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SHARE, BY END USER AND COUNTRY (2020)
           FIGURE 14 HOSPITALS & DIAGNOSTIC LABORATORIES SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC IHC MARKET IN 2020
    4.3 IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE
           FIGURE 15 PRIMARY ANTIBODIES SEGMENT TO LEAD IHC ANTIBODIES MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 66)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 16 IHC MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           TABLE 2 IHC MARKET: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Rising geriatric population and subsequent growth in prevalence of chronic and infectious diseases
                               TABLE 3 ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION (2019–2050)
                               FIGURE 17 CANCER INCIDENCE, BY REGION AND TYPE OF CANCER, 2020
                    5.2.1.2 Technological advancements in IHC
                    5.2.1.3 Availability of reimbursements for IHC tests
                               TABLE 4 CPT CODES FOR IHC PROCEDURES
           5.2.2 RESTRAINTS
                    5.2.2.1 High degree of consolidation
                               TABLE 5 MAJOR ACQUISITIONS IN THE MARKET, 2018–2021
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increasing demand for personalized medicine
                    5.2.3.2 Growing significance of companion diagnostics
                    5.2.3.3 Growth opportunities in emerging countries
           5.2.4 CHALLENGES
                    5.2.4.1 Dearth of skilled professionals
                               TABLE 6 NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 2018
                    5.2.4.2 Product failures and recalls
    5.3 RANGES/SCENARIO
           FIGURE 18 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF IHC MARKET
    5.4 IMPACT OF COVID-19 OUTBREAK ON IHC MARKET
           FIGURE 19 IHC MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019-2021
    5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
           FIGURE 20 REVENUE SHIFT & NEW POCKET FOR IHC PROVIDERS
    5.6 PRICING ANALYSIS
           TABLE 7 AVERAGE SELLING PRICE OF SOME IHC EQUIPMENT, REAGENTS, AND KITS (2020)
    5.7 VALUE CHAIN ANALYSIS
           FIGURE 21 VALUE CHAIN ANALYSIS OF IHC MARKET: RAW MATERIAL AND MANUFACTURING PHASE CONTRIBUTES MAXIMUM VALUE
    5.8 ECOSYSTEM ANALYSIS
           FIGURE 22 ECOSYSTEM ANALYSIS: IHC MARKET
           TABLE 8 SUPPLY CHAIN ECOSYSTEM
    5.9 TECHNOLOGY ANALYSIS
    5.10 PATENT ANALYSIS
           FIGURE 23 PATENT GRANTED FOR IHC IN LAST 10 YEARS
           TABLE 9 INDICATIVE LIST OF PATENTS IN IHC MARKET
    5.11 REGULATORY ANALYSIS
           5.11.1 US
                    TABLE 10 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES
                    FIGURE 24 US: REGULATORY PROCESS FOR IVD DEVICES
           5.11.2 CANADA
                     FIGURE 25 CANADA: REGULATORY PROCESS FOR IVD DEVICES
           5.11.3 EUROPE
                     TABLE 11 EUROPE: CLASSIFICATION OF IVD DEVICES
                     FIGURE 26 EUROPE: REGULATORY PROCESS FOR IVD DEVICES
           5.11.4 JAPAN
                     FIGURE 27 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
                     TABLE 12 JAPAN: CLASSIFICATION OF IVD REAGENTS
                     TABLE 13 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.11.5 CHINA
                     TABLE 14 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.11.6 INDIA
                     FIGURE 28 INDIA: REGULATORY PROCESS FOR IVD DEVICES
           5.11.7 BRAZIL
                     FIGURE 29 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
    5.12 PORTER’S FIVE FORCES ANALYSIS
           TABLE 15 IHC MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.12.1 THREAT OF NEW ENTRANTS
           5.12.2 THREAT OF SUBSTITUTES
           5.12.3 BARGAINING POWER OF BUYERS
           5.12.4 BARGAINING POWER OF SUPPLIERS
           5.12.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS

6 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT (Page No. - 94)
    6.1 INTRODUCTION
           TABLE 16 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
    6.2 ANTIBODIES
           TABLE 17 IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY REGION, 2019–2026 (USD MILLION)
           TABLE 18 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 19 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 20 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 21 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY REGION, 2019–2026 (USD MILLION)
           TABLE 22 IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
           6.2.1 PRIMARY ANTIBODIES
                    6.2.1.1 Wide applications in diagnostics and research to support demand for primary antibodies
                               TABLE 23 IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 24 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 25 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 26 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 27 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY REGION, 2019–2026 (USD MILLION)
           6.2.2 SECONDARY ANTIBODIES
                    6.2.2.1 Signal amplification through conjugation and comparatively easy manufacturing to drive market for secondary antibodies
                               TABLE 28 IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 29 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 30 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 31 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 32 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY REGION, 2019–2026 (USD MILLION)
    6.3 REAGENTS
           TABLE 33 IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY REGION, 2019–2026 (USD MILLION)
           TABLE 34 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 35 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 36 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 37 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY REGION, 2019–2026 (USD MILLION)
           TABLE 38 IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
           6.3.1 HISTOLOGICAL STAINS
                    6.3.1.1 Developments in concurrent detection of multiple antigenic sites within single tissue specimen and cancer disease progression studies to propel market growth
                               TABLE 39 IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 40 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 41 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 42 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 43 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY REGION, 2019–2026 (USD MILLION)
           6.3.2 BLOCKING SERA AND REAGENTS
                    6.3.2.1 Blocking sera and reagents prevent nonspecific binding and reduce background noise and potentially false-positive results
                               TABLE 44 IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 45 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 46 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 47 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 48 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY REGION, 2019–2026 (USD MILLION)
           6.3.3 CHROMOGENIC SUBSTRATES
                    6.3.3.1 Chromogenic substrates segment to register highest growth during forecast period
                               TABLE 49 IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 50 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 51 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 52 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 53 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES, BY REGION, 2019–2026 (USD MILLION)

           6.3.4 FIXATION REAGENTS
                    6.3.4.1 North America is largest market for fixation reagents
                               TABLE 54 IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 55 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 56 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 57 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 58 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY REGION, 2019–2026 (USD MILLION)
           6.3.5 DILUENTS
                    6.3.5.1 Diluents are used to prepare antibody solutions
                               TABLE 59 IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 60 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 61 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 62 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 63 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY REGION, 2019–2026 (USD MILLION)
           6.3.6 ORGANIC SOLVENTS
                    6.3.6.1 Organic solvents prevent physical damage in specimens and improve clarity while visualizing tissue samples
                               TABLE 64 IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 65 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 66 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 67 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 68 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY REGION, 2019–2026 (USD MILLION)
           6.3.7 PROTEOLYTIC ENZYMES
                    6.3.7.1 Proteolytic enzymes improve accessibility of target antibodies
                               TABLE 69 IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 70 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 71 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 72 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 73 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES, BY REGION, 2019–2026 (USD MILLION)
           6.3.8 OTHER REAGENTS
                    6.3.8.1 Other reagents include antigen retrieval solutions, stabilizers, controls, and mounting solutions
                               TABLE 74 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 75 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 76 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 77 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 78 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY REGION, 2019–2026 (USD MILLION)
    6.4 EQUIPMENT
           TABLE 79 IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY REGION, 2019–2026 (USD MILLION)
           TABLE 80 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 81 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 82 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 83 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY REGION, 2019–2026 (USD MILLION)
           TABLE 84 IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
           6.4.1 SLIDE-STAINING SYSTEMS
                    6.4.1.1 Development of high throughput staining systems to drive market growth
                               TABLE 85 IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 86 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 87 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 88 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 89 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
           6.4.2 TISSUE PROCESSING SYSTEMS
                    6.4.2.1 Technological advancements and need for automation due to shortage of skilled workforce to drive market growth
                               TABLE 90 IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 91 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 92 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 93 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 94 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY REGION, 2019–2026 (USD MILLION)
           6.4.3 SLIDE SCANNERS
                    6.4.3.1 Development of advanced multiplexed IHC scanners to drive market growth
                               TABLE 95 IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 96 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 97 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 98 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 99 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY REGION, 2019–2026 (USD MILLION)
           6.4.4 OTHER EQUIPMENT
                    TABLE 100 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 101 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 102 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 103 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 104 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY REGION, 2019–2026 (USD MILLION)
    6.5 KITS
           TABLE 105 IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY REGION, 2019–2026 (USD MILLION)
           TABLE 106 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 107 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 108 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 109 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY REGION, 2019–2026 (USD MILLION)
           TABLE 110 IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE, 2019–2026 (USD MILLION)
           6.5.1 HUMAN IMMUNOHISTOCHEMISTRY KITS
                    6.5.1.1 Increasing focus on cancer research to fuel market growth
                               TABLE 111 IMMUNOHISTOCHEMISTRY MARKET FOR HUMAN IMMUNOHISTOCHEMISTRY KITS, BY REGION, 2019–2026 (USD MILLION)
           6.5.2 ANIMAL IMMUNOHISTOCHEMISTRY KITS
                    6.5.2.1 Increasing preclinical drug testing to drive market growth
                               TABLE 112 IMMUNOHISTOCHEMISTRY MARKET FOR ANIMAL IMMUNOHISTOCHEMISTRY KITS, BY REGION, 2019–2026 (USD MILLION)

7 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION (Page No. - 136)
    7.1 INTRODUCTION
           TABLE 113 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
    7.2 DIAGNOSTIC APPLICATIONS
           TABLE 114 IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
           TABLE 115 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 116 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 117 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 118 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
           TABLE 119 IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
           7.2.1 CANCER
                    7.2.1.1 Growing use of IHC tests for cancer diagnostics to fuel market growth
                               TABLE 120 COMMON CANCER MARKERS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS
                               TABLE 121 IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 122 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 123 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 124 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 125 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY REGION, 2019–2026 (USD MILLION)
           7.2.2 INFECTIOUS DISEASES
                    7.2.2.1 Growing prevalence of infectious diseases and rising awareness of early diagnosis to propel market growth
                               TABLE 126 COMMON INFECTIOUS DISEASE MARKERS/ANTIGENS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS
                               TABLE 127 IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 128 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 129 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 130 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 131 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019–2026 (USD MILLION)
           7.2.3 NEPHROLOGICAL DISEASES
                    7.2.3.1 Wide application of IHC in transplant rejection expected to support market growth
                               TABLE 132 IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 133 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 134 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 135 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 136 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2019–2026 (USD MILLION)
           7.2.4 AUTOIMMUNE DISEASES
                    7.2.4.1 Availability of numerous primary antibodies and rapid processing of results makes IHC a favorable diagnostic approach
                               TABLE 137 IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 138 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 139 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 140 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 141 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2019–2026 (USD MILLION)
           7.2.5 NEUROLOGICAL DISEASES
                    7.2.5.1 Increasing global burden of neurological diseases to propel market growth
                               TABLE 142 COMMON IMMUNOHISTOCHEMISTRY MARKERS FOR CENTRAL NERVOUS SYSTEM
                               TABLE 143 IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2019–2026 (USD MILLION)
                               TABLE 144 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 145 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 146 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                               TABLE 147 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2019–2026 (USD MILLION)
           7.2.6 OTHER DISEASES
                    TABLE 148 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 149 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 150 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 151 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 152 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY REGION, 2019–2026 (USD MILLION)
    7.3 RESEARCH APPLICATIONS
           TABLE 153 IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
           TABLE 154 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 155 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 156 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 157 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
           TABLE 158 IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION)
           7.3.1 DRUG DEVELOPMENT & TESTING
                    7.3.1.1 Quantitative image analysis makes IHC techniques ideal for drug testing
                               TABLE 159 IMMUNOHISTOCHEMISTRY MARKET FOR DRUG DEVELOPMENT & TESTING, BY REGION, 2019–2026 (USD MILLION)
           7.3.2 OTHER RESEARCH APPLICATIONS
                    TABLE 160 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
    7.4 FORENSIC APPLICATIONS
           TABLE 161 IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)
           TABLE 162 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 163 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 164 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 165 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY REGION, 2019–2026 (USD MILLION)

8 IMMUNOHISTOCHEMISTRY MARKET, BY END USER (Page No. - 161)
    8.1 INTRODUCTION
           TABLE 166 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
    8.2 HOSPITALS & DIAGNOSTIC LABORATORIES
           8.2.1 INCREASING INCIDENCE OF CANCER AND INFECTIOUS DISEASES TO INCREASE TESTING VOLUME IN CLINICAL LABORATORIES
                    TABLE 167 IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 168 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 169 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 170 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 171 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2019–2026 (USD MILLION)
    8.3 ACADEMIC & RESEARCH INSTITUTES
           8.3.1 INCREASING USE OF IHC TESTS FOR DRUG DEVELOPMENT AND DISEASES DIAGNOSIS TO SUPPORT MARKET GROWTH
                    TABLE 172 IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION)
                    TABLE 173 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 174 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 175 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
                    TABLE 176 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION)
    8.4 OTHER END USERS
           TABLE 177 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)
           TABLE 178 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 179 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 180 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 181 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)

9 IMMUNOHISTOCHEMISTRY MARKET, BY REGION (Page No. - 169)
    9.1 INTRODUCTION
           FIGURE 30 IMMUNOHISTOCHEMISTRY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           TABLE 182 IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2019–2026 (USD MILLION)
    9.2 NORTH AMERICA
           FIGURE 31 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT
           TABLE 183 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 184 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 185 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 186 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 187 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 188 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 189 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
           TABLE 190 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.2.1 US
                    9.2.1.1 US is largest country-level market for immunohistochemistry
                               TABLE 191 RECENT DEVELOPMENTS IN US IHC MARKET
                               TABLE 192 US: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 193 US: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 194 US: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 195 US: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 196 US: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                               TABLE 197 US: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
                               TABLE 198 US: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Increasing cancer cases in Canada to propel market growth
                               TABLE 199 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 200 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 201 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 202 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 203 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                               TABLE 204 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
                               TABLE 205 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
    9.3 EUROPE
           TABLE 206 RECENT DEVELOPMENTS IN EUROPEAN IHC MARKET
           TABLE 207 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 208 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 209 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 210 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 211 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 212 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 213 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
           TABLE 214 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Germany to dominate European IHC market
                               TABLE 215 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 216 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 217 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 218 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 219 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                               TABLE 220 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
                               TABLE 221 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.3.2 FRANCE
                    9.3.2.1 Increasing use of IHC in cancer diagnosis and research to drive market growth
                               TABLE 222 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 223 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 224 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 225 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 226 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                               TABLE 227 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
                               TABLE 228 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.3.3 UK
                    9.3.3.1 Increasing number of cancer research studies to support market growth
                               TABLE 229 UK: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 230 UK: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 231 UK: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 232 UK: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 233 UK: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                               TABLE 234 UK: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
                               TABLE 235 UK: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 High incidence of cancer and rising geriatric population to support market growth in Italy
                               TABLE 236 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 237 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 238 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 239 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 240 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                               TABLE 241 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
                               TABLE 242 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 Increasing demand for personalized medicine will drive demand for IHC tests to find potential biomarkers
                               TABLE 243 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 244 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 245 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 246 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 247 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                               TABLE 248 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
                               TABLE 249 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.3.6 REST OF EUROPE
                    TABLE 250 ROE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                    TABLE 251 ROE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 252 ROE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 253 ROE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 254 ROE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                    TABLE 255 ROE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
                    TABLE 256 ROE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
    9.4 ASIA PACIFIC
           FIGURE 32 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT
           TABLE 257 RECENT DEVELOPMENTS IN ASIA PACIFIC IHC MARKET
           TABLE 258 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 259 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 260 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 261 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 262 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 263 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 264 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
           TABLE 265 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.4.1 JAPAN
                    9.4.1.1 Japan to dominate Asia Pacific immunohistochemistry market
                               TABLE 266 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 267 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 268 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 269 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 270 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                               TABLE 271 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
                               TABLE 272 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.4.2 CHINA
                    9.4.2.1 China to register highest growth during forecast period
                               TABLE 273 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 274 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 275 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 276 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 277 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                               TABLE 278 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
                               TABLE 279 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 India is key destination for high-end pathology and diagnostic services
                               TABLE 280 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 281 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 282 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 283 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 284 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                               TABLE 285 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
                               TABLE 286 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.4.4 REST OF ASIA PACIFIC
                    TABLE 287 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                    TABLE 288 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 289 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 290 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 291 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                    TABLE 292 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
                    TABLE 293 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
    9.5 REST OF THE WORLD
           TABLE 294 ROW: IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2019–2026 (USD MILLION)
           TABLE 295 ROW: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
           TABLE 296 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 297 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 298 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 299 ROW: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
           TABLE 300 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
           TABLE 301 ROW: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.5.1 LATIN AMERICA
                    9.5.1.1 Increasing incidence of cancer in Latin America driving market growth
                               TABLE 302 LATAM: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 303 LATAM: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 304 LATAM: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 305 LATAM: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 306 LATAM: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                               TABLE 307 LATAM: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
                               TABLE 308 LATAM: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)
           9.5.2 MIDDLE EAST AND AFRICA
                    9.5.2.1 Government initiatives focused on boosting healthcare infrastructure development to drive market growth
                               TABLE 309 MEA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                               TABLE 310 MEA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 311 MEA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 312 MEA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2019–2026 (USD MILLION)
                               TABLE 313 MEA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                               TABLE 314 MEA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2019–2026 (USD MILLION)
                               TABLE 315 MEA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2019–2026 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 226)
     10.1 OVERVIEW
     10.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN
             FIGURE 33 KEY PLAYERS STRATEGIES IN IMMUNOHISTOCHEMISTRY MARKET, 2019- 2021
     10.3 MARKET SHARE ANALYSIS
             FIGURE 34 IMMUNOHISTOCHEMISTRY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
     10.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
             FIGURE 35 TOP MARKET PLAYERS DOMINATED IMMUNOHISTOCHEMISTRY MARKET FOR PAST 5 YEARS
     10.5 COMPANY EVALUATION QUADRANT
             10.5.1 STARS
             10.5.2 EMERGING LEADERS
             10.5.3 PERVASIVE
             10.5.4 EMERGING COMPANIES
                        FIGURE 36 IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION QUADRANT, 2020
     10.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
             10.6.1 PROGRESSIVE COMPANIES
             10.6.2 STARTING BLOCKS
             10.6.3 RESPONSIVE COMPANIES
             10.6.4 DYNAMIC COMPANIES
                        FIGURE 37 IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
     10.7 COMPANY PRODUCT FOOTPRINT
             TABLE 316 PRODUCT PORTFOLIO ANALYSIS: IMMUNOHISTOCHEMISTRY MARKET (2020)
     10.8 COMPANY GEOGRAPHIC FOOTPRINT
             TABLE 317 GEOGRAPHIC REVENUE MIX: IMMUNOHISTOCHEMISTRY MARKET (2020)
     10.9 COMPETITIVE SCENARIO
             10.9.1 IMMUNOHISTOCHEMISTRY MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2019–MARCH 2021
             10.9.2 IMMUNOHISTOCHEMISTRY MARKET: DEALS, JANUARY 2019–MARCH 2021
             10.9.3 IMMUNOHISTOCHEMISTRY MARKET: OTHER DEVELOPMENTS, JANUARY 2019–MARCH 2021

11 COMPANY PROFILES (Page No. - 240)
     11.1 KEY COMPANIES
(Business overview, Products and Services offered, Recent developments, MNM view)* 
             11.1.1 F. HOFFMANN-LA ROCHE AG
                        TABLE 318 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
                        FIGURE 38 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2020)
             11.1.2 DANAHER CORPORATION
                        TABLE 319 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
             11.1.3 AGILENT TECHNOLOGIES, INC.
                        TABLE 320 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
                        FIGURE 40 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020)
             11.1.4 MERCK KGAA
                        TABLE 321 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 41 MERCK KGAA: COMPANY SNAPSHOT (2020)
             11.1.5 BIO-RAD LABORATORIES, INC.
                        TABLE 322 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 42 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020)
             11.1.6 BIO-TECHNE CORPORATION
                        TABLE 323 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW
                        FIGURE 43 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2020)
             11.1.7 ABCAM PLC
                        TABLE 324 ABCAM PLC: BUSINESS OVERVIEW
                        FIGURE 44 ABCAM PLC: COMPANY SNAPSHOT (2020)
             11.1.8 BECTON, DICKINSON AND COMPANY
                        TABLE 325 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 45 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
             11.1.9 PERKINELMER, INC.
                        TABLE 326 PERKINELMER, INC.: BUSINESS OVERVIEW
                        FIGURE 46 PERKINELMER, INC.: COMPANY SNAPSHOT (2020)
             11.1.10 TAKARA BIO, INC.
                        TABLE 327 TAKARA BIO, INC.: BUSINESS OVERVIEW
                        FIGURE 47 TAKARA BIO, INC.: COMPANY SNAPSHOT (2020)
             11.1.11 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 328 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 48 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)
             11.1.12 PHC HOLDINGS CORPORATION
                        TABLE 329 PHC HOLDINGS CORPORATION: BUSINESS OVERVIEW
             11.1.13 CELL SIGNALING TECHNOLOGY, INC.
                        TABLE 330 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW
             11.1.14 BIO SB, INC.
                        TABLE 331 BIO SB, INC.: BUSINESS OVERVIEW
             11.1.15 MILTENYI BIOTEC
                        TABLE 332 MILTENYI BIOTEC: BUSINESS OVERVIEW
             11.1.16 CANDOR BIOSCIENCE GMBH
                        TABLE 333 CANDOR BIOSCIENCE GMBH: BUSINESS OVERVIEW
             11.1.17 SAKURA FINETEK JAPAN CO., LTD.
                        TABLE 334 SAKURA FINETEK JAPAN CO., LTD.: BUSINESS OVERVIEW
     11.2 OTHER PLAYERS
             11.2.1 EAGLE BIOSCIENCES, INC.
                        TABLE 335 EAGLE BIOSCIENCES, INC.: COMPANY OVERVIEW
             11.2.2 BIOCARE MEDICAL, LLC
                        TABLE 336 BIOCARE MEDICAL, LLC: COMPANY OVERVIEW
             11.2.3 ELABSCIENCE, INC.
                        TABLE 337 ELABSCIENCE, INC.: COMPANY OVERVIEW
             11.2.4 BIO-GENEX LABORATORIES
                        TABLE 338 BIO-GENEX LABORATORIES: COMPANY OVERVIEW
             11.2.5 DIAGNOSTIC BIOSYSTEMS, INC.
                        TABLE 339 DIAGNOSTIC BIOSYSTEMS, INC.: COMPANY OVERVIEW
             11.2.6 BIOVISION, INC.
                        TABLE 340 BIOVISION, INC.: COMPANY OVERVIEW
             11.2.7 ROCKLAND IMMUNOCHEMICALS, INC.
                        TABLE 341 ROCKLAND IMMUNOCHEMICALS, INC.: COMPANY OVERVIEW
             11.2.8 GENEMED BIOTECHNOLOGIES, INC.
                        TABLE 342 GENEMED BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW
*Business overview, Products and Services offered, Recent developments, MNM view might not be captured in case of unlisted companies. 

12 APPENDIX (Page No. - 346)
     12.1 DISCUSSION GUIDE
     12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.3 AVAILABLE CUSTOMIZATIONS
     12.4 RELATED REPORTS
     12.5 AUTHOR DETAILS

This market research study involves the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global immunohistochemistry market. Interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market prospects. The immunohistochemistry market size was estimated through various secondary research approaches and triangulated with inputs from primary research.

Secondary Research

The secondary sources referred to for this research study include publications from government sources [such as the World Bank, World Health Organization (WHO), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Centre for Biotechnology Information (NCBI), Therapeutic Goods Administration (TGA), and Centers for Disease Control and Prevention (CDC)]; sites like ClinicalTrials.gov, fiercebiotech, and annual reports; SEC filings; press releases; investor presentations; journals; expert interviews; MarketsandMarkets analysis; business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global immunohistochemistry market, which was validated through primary research.

Primary Research

After acquiring basic knowledge about the global immunohistochemistry market scenario through secondary research, extensive primary research was conducted. Several primary interviews were conducted with market experts from both the OEMs and supply and the demand side participants (such as clinical diagnostic laboratories, hospitals, etc. ) across four major regions—North America, Europe, the Asia Pacific, and the Rest of the World. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews. The following is a breakdown of the primary respondents:

Immunohistochemistry (IHC) Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the immunohistochemistry market was estimated through different approaches. A detailed market estimation approach was followed to estimate and validate the global market value and other dependent submarkets, as mentioned below. Both top-down and bottom-up approaches were used to estimate and validate the total size of the biosimilars market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the immunohistochemistry business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, segment, and forecast the immunohistochemistry market based on product, application, end user, and region
  • To provide detailed information about the factors influencing market growth, such as drivers, restraints, opportunities, and challenges
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to four main regions, namely,
    North America, Europe, the Asia Pacific (APAC), and the Rest of the World (RoW)
  • To profile the key market players and comprehensively analyze their core competencies and market rankings
  • To track and analyze competitive developments, such as product launches, acquisitions, expansions, and partnerships, in the immunohistochemistry market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographic Analysis

  • Further breakdown of the European immunohistochemistry market into countries from the Rest of Europe.
  • Further breakdown of the Asia Pacific immunohistochemistry market into countries from the Rest of the APAC.
  • Further breakdown of the Latin America immunohistochemistry market into Brazil, Mexico, and the Rest of Latin America.

Company Information

Detailed analysis and profiling of additional market players (up to 5), inclusive of:

  • Business Overview
  • Financial Information
  • Product Portfolio
  • Developments (Last Three Years)
COVID-19

Get in-depth analysis of the COVID-19 impact on the Immunohistochemistry (IHC) Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Immunohistochemistry (IHC) Market

Request For Special Pricing
Report Code
BT 4780
Published ON
Nov, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Immunohistochemistry (IHC) Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved